



# VACCINE FACT SHEET

PRESENTED BY THE GOP DOCTORS CAUCUS

**Founded on May 15, 2020**, Operation Warp Speed has supported the research, development, or manufacturing of six prospective vaccines. To date, three of those vaccines have published information from trials pertaining to efficacy.

## **Pfizer**

**Efficacy:** 95%

**Doses:** 2 doses; 21 days apart

**Storing Temperature:** -94°F

### **OWS Funding:**

- Pfizer's COVID-19 vaccine development costs were self-funded.
- In July, HHS announced up to \$1.95 billion in funds to Pfizer and BioNTech for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate.

**Trial Participants:** Over 43,000 participants. Select sites continue to enroll participants.

**EUA Timeline:** EUA application with the FDA filed on Friday, November 20th, 2020.

**Fetal Cell Line Interaction:** Human fetal derived cell lines are not used to produce the vaccine, which consists of synthetic and enzymatically produced components. Some (but not all) laboratory tests use cells of fetal origin.



## **Moderna**

**Efficacy:** 94.5%

**Doses:** 2 doses; four weeks apart

**Storing Temperature:** Stable at -4°F for up to six months and 36° to 46°F (temperature of a standard home or medical refrigerator) for 30 days and at room temperature for up to 12 hours.

### **OWS Funding:**

- In April, HHS made up to \$483 million in support available for Moderna's vaccine candidate.
- In August, OWS announced up to a \$1.5 billion agreement with Moderna to produce 100 million doses of the vaccine candidate, manufacturing in parallel with clinical trials to expedite the traditional vaccine development timeline.

**Trial Participants:** Enrollment closed at over 30,000 participants.

**EUA Timeline:** EUA application with the FDA filed on Monday, November 30th, 2020.

**Fetal Cell Line Interaction:** Some (but not all) confirmatory lab tests used cells of fetal origin. Design, development, and production did not.



## **AstraZeneca**



**Efficacy:** 90% in trials in the U.K. in which recipients received 1/2 dose and then 1 full dose at least one month later; 62% in trials in which recipients received 1 full dose and then a second full dose about a month later (in UK and Brazil). *Efficacy data for U.S. trials has not been reported yet.*

**Doses:** Two doses; approximately one month apart

**Storing Temperature:** Normal refrigeration temperatures, 6 month shelf life

**OWS Funding:**

- In May, OWS announced up to \$1.2 billion in support of AstraZeneca's vaccine candidate to make available at least 300 million doses of the vaccine for the United States.

**Trial Participants:** AstraZeneca is still accepting trial participants.

**EUA Timeline:** AstraZeneca plans to apply for an EUA after reaching key safety and efficacy milestones.

**Fetal Cell Line Interaction:** Cells of fetal origin were used in the design, development, production, and confirmatory lab tests.